Metabolic effects of prolonged sympathetic nerve stimulation in canine subcutaneous adipose tissue.
D000273:Adipose Tissue / Q000378:metabolism*; D000317:Adrenergic alpha-Antagonists / Q000494:pharmacology; D000319:Adrenergic beta-Antagonists / Q000494:pharmacology; D000818:Animals; D002245:Carbon Dioxide / Q000378:metabolism; D004285:Dogs; D004558:Electric Stimulation; D004878:Ergotamine / Q000494:pharmacology; D005230:Fatty Acids, Nonesterified / Q000378:metabolism; D005260:Female; D005947:Glucose / Q000378:metabolism; D005990:Glycerol / Q000378:metabolism; D006003:Glycogen / Q000378:metabolism; D007773:Lactates / Q000378:metabolism; D008053:Lipid Mobilization; D010101:Oxygen Consumption; D011433:Propranolol / Q000494:pharmacology; D011773:Pyruvates / Q000378:metabolism; D011984:Sensory Receptor Cells; D013564:Sympathetic Nervous System / Q000502:physiology*
D000317:Adrenergic alpha-Antagonists; D000319:Adrenergic beta-Antagonists; D005230:Fatty Acids, Nonesterified; D007773:Lactates; D011773:Pyruvates; D002245:Carbon Dioxide; D006003:Glycogen; D011433:Propranolol; D005947:Glucose; D005990:Glycerol; D004878:Ergotamine